Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases

Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases

US Patent 8536185 · Granted Sep 17, 2013

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Ready-to-extract platforms for chemical analysis and quantification of unknown s2024
Cannabinoid conjugate molecules2024
Cannabinoid conjugate molecules2024
Difluorolactam compounds as EP4 receptor-selective agonists for use in the treat2024
Difluorolactam compounds as EP4 receptor-selective agonists for use in the treat2024
Difluorolactam compounds as EP4 receptor-selective agonists for use in the treat2024
Difluorolactam compounds as EP4 receptor-selective agonists for use in the treat2024
Cannabinoid conjugate molecules2023
Methods of synthesizing a difluorolactam analog2022
Methods of synthesizing a difluorolactam analog2022
Difluorolactam compounds as EP4 receptor-selective agonists for use in the treat2021
Difluorolactam compounds as EP4 receptor-selective agonists for use in the treat2021